Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40021852
Localisation
Japan
Asia
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
25/09/2025
Statut
Classification
1.5°C
Année cible
FY2030
Near-Term Targets: Asahi Kasei Life Science Corp. commits to reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from a FY2023 base year. Asahi Kasei Life Science Corp. also commits to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel- and energy-related activities, waste generated in operations, and end-of-life treatment of sold products 25% within the same timeframe. Asahi Kasei Life Science Corp. further commits that 60% of its suppliers by emissions, covering upstream transportation and distribution, will have science-based targets by FY2030.
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
Source : Science Based Targets initiative | Données publiques